Floatz logo

(+)-VINCRISTINE

Relapsing Chronic Myelogenous Leukemia

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Relapsing Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Benadryl
City of Hope Medical Center
Phase 2BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Cediranib
M.D. Anderson Cancer Center
Phase 2BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Vorinostat
OHSU Knight Cancer Institute
Phase 2B

View all 17 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →